



## **Dynavax to Webcast Presentations at Upcoming Healthcare Conferences**

BERKELEY, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Dynavax Technologies (Nasdaq: DVAX) announced today that Dino Dina, MD, President, CEO and Director, will present an overview of the company at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference at the New York Palace Hotel, and at the CIBC World Markets 16th Annual Healthcare Conference at the Waldorf-Astoria in New York City.

Dr. Dina's presentation at the Rodman & Renshaw Techvest Conference will be webcast live at 8:40 am ET on Monday, November 7, 2005, and may be accessed by visiting: <http://www.wsw.com/webcast/rrshq7/dvax/> . The CIBC World Markets Conference presentation will be webcast live at 2 p.m. ET on Tuesday, November 8, 2005, and may be accessed at: <http://www.veracast.com/webcasts/cibcwm/hc05/52211473.cfm> .

Both presentations may also be accessed by visiting the Dynavax website at <http://www.dynavax.com> under the Investors section where they will also be archived for 30 days following the presentation.

### **About Dynavax**

Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Our clinical development programs are based on immunostimulatory sequences, or ISS, which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. Dynavax's pipeline includes: TOLAMBA™, a ragweed allergy immunotherapeutic, currently in a large-scale Phase 2b clinical trial, and in a supportive clinical trial in ragweed allergic children; HEPLISAV™, a hepatitis B vaccine that is currently in a pivotal Phase 3 clinical trial; a cancer therapy currently in a Phase 2 clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase 2a clinical trial.

SOURCE Dynavax Technologies Corporation

10/25/2005

CONTACT: Jane M. Green, PhD, Vice President, Corporate Communications of Dynavax Technologies Corporation, +1-510-665-4630, or [jgreen@dvax.com](mailto:jgreen@dvax.com)

Web site: <http://www.dynavax.com>

(DVAX)

10/25/2005 16:00 EDT <http://www.prnewswire.com>